WuXi Biologics (Cayman) Inc. has been recognized by the Hong Kong ESG Reporting Awards $(HERA)$ 2025 for Outstanding ESG Disclosure. This follows the company’s previous receipt of the ESG Report Benchmark Award from HERA in the prior year. WuXi Biologics reports on sustainability targets and progress in areas including corporate governance, talent development, and greenhouse gas emission reduction. The company participates in initiatives such as the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative $(PSCI)$, and has received several ESG-related ratings and recognitions, including an MSCI AAA Rating, EcoVadis Platinum Medal, inclusion in the Dow Jones Sustainability Indices, and an “A List” rating by CDP for Climate Change, Water Security, and Supplier Engagement Assessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on December 24, 2025, and is solely responsible for the information contained therein.